

CONTACT:
Steve Hanley
MediBeacon LLC
Office - 314-269-5808
Email - Hanley@medibeacon.com
www.medibeacon.com

NEWS UPDATE

SPIE Photonics West Highlights Translational Research

MediBeacon[™] Presentation Highlighted as Bench-to-Bedside Translational Research

(SAN FRANCISCO, February 3, 2014) – Dr. Richard B. Dorshow, Ph.D., President, Chief Scientific Officer and Founder of MediBeacon presented safety and toxicology data on the MediBeacon renal function tracer agent APC-2 at the International Biomedical Optics Symposium (BiOS 2014) on February 3, 2014 in San Diego.

BiOS is the world's largest biomedical optics conference. It is held annually as part of SPIE Photonics West. SPIE Photonics West is the largest and most influential conference (20,000 attendees, two exhibitions, 1,300 exhibiting companies, 4,500+ papers) for biophotonics, biomedical optics, translational research, industrial lasers, optoelectronics, microfabrication, optical MEMs, and more.



The talk entitled "Initial Formal Toxicity Evaluation of APC-2, a Novel Fluorescent Tracer Agent for Real-Time Measurement of Glomerular Filtration Rate in Preparation for a first-in-man clinical trial", co-authored by Joseph E. Bugaj and Richard B. Dorshow, was part of the highlighted presentations on bench-to-bedside translational research.

The talk covered:

- Design, synthesis, and GMP manufacturing of an entirely new fluorescent agent for the specific unmet medical need of renal function measurement at the bedside
- · Completion of all safety, pharmacology, and toxicity assays required for first-in-human studies
- Commencement of first-in-human studies in the United States

Current clinically employed techniques lack sensitivity or are cumbersome to use. MediBeacon is developing technology that employs an exogenous fluorescent tracer agent to measure glomerular filtration rate (GFR) by noninvasively monitoring through skin. This is expected to be a substantial improvement over currently available methods.

A manuscript for submission to a peer-reviewed journal is under preparation. The proceedings paper will be available at www.medibeacon.com/news.

About MediBeacon, LLC:

MediBeacon LLC is a Medical Device company focused initially on kidney function monitoring in real-time. MediBeacon is housed within the Helix Center Biotech Incubator. Information regarding MediBeacon can be found at www.medibeacon.com.

#